EN
 
EN

Please select one of our websites from the list below.

  1. Africa

    1. North Africa
      1. | Français
  2. Americas

    1. United States
      1. English
    2. Canada
      1. English
      2. | Français
  3. Asia

    1. Middle East
      1. عربى
    2. Vietnam
      1. Vietnamese
  4. Europe

    1. Germany
      1. Deutsch
    2. Russia
      1. Russian
    3. Spain
      1. Español
    4. Austria
      1. German
    5. Finland
      1. Suomi
  5. Pacific

    1. Australia
      1. English

Mylan also is proud to do business in these locations.

A WORLD OF CARE

Biologic medicines have become the standard of care for many serious diseases like cancer, autoimmune disorders, and diabetes.

biosimilars without borders

Mylan's belief is that 7 billion people across the globe deserve access to the treatments they need. As one part of this broader cause, we are working to make biologics more accessible.


WHAT ARE BIOSIMILARS

marvels of modern science

Biologics have revolutionized the treatment of many diseases. Biosimilar medicines offer physicians additional therapeutic options to essential, but often expensive biologic products. Unlike conventional medicines, which are made up of chemical compounds, biologics are complex products composed of proteins, sugars or nucleic acids, or may be living entities such as cells and tissues.

Biologics are highly complex and often expensive therapies.

A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.

A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

  • WHAT IS A BIOSIMILAR?

    Biologics are highly complex and often expensive therapies. 

    A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. 

    This similarity is confirmed through a number of tests, both in the lab and in clinical research. A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

  • WHAT IS A BIOSIMILAR?

    Biologics are highly complex and often expensive therapies.

    A biosimilar is a biologic deemed highly similar to an already approved biologic medicine, known as a reference product. This similarity is confirmed through a number of tests, both in the lab and in clinical research.

    A biosimilar manufacturer must demonstrate that its proposed biosimilar product has no clinically meaningful differences from the reference product in terms of safety, purity, and effectiveness.

Biosimilars Reach
Biosimilars Reach
Biosimilars Reach

EXPANDING ACCESS

we reach people

The most advanced drugs are of no use if patients don’t have access to them. Biologics are a case in point.

Total Canadian spending on biologics continues to increase, accounting for $8.3 billion in 2018 up from $5.1 billion in 2013. In 2018, that $8.3 billion in spending represented only 1.1% of public and 2.4% of private claims. Of the top 10 most costly biologics in Canada, Mylan has 7 currently in development.

There is an urgent need for biologics in many underserved regions, countries and emerging markets around the world.

Mylan has successfully introduced biosimilars in over 25 countries. What others hope to do in the future, Mylan is delivering today.

For nearly 60 years, Mylan’s mission has been to provide access to medicine. Today our workforce of ~35,000 serves patients in >165 countries and territories, and we offer a growing portfolio of more than 7,500 medicines, including branded, generic and consumer health products. You may not realize that Mylan provides ~69 billion doses of medicine annually.

Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who benefit - governments and insurers do, too.

  • NO MATTER WHERE

    OVER 25 COUNTRIES GLOBALLY

    There is an urgent need for biologics in many underserved regions, countries and emerging markets around the world.

    Mylan has successfully introduced biosimilars in over 25 countries. What others hope to do in the future, Mylan is delivering today.

  • ITS WHAT WE DO

    For more than 55 years, Mylan has championed the right of patients everywhere to high quality, affordable medicines.

    Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics, and potentially increasing access to treatment. It's not just patients who benefit - governments and insurers do, too.

Biosimilars Value
Biosimilars Value

A COMMITMENT TO BIOSIMILARS

biosimilars add value

Every biosimilar we add to our portfolio provides more patients in more countries with the treatment they need. We are committed to continue investing in biosimillars.

We have one of the industry’s largest and most diverse portfolios: including 20 biosimilars and insulin analogs.

Our portfolio includes many of the top biologics globally and focuses on the areas of oncology, immunology, endocrinology and ophthalmology.

DIABETES & METABOLICS

ONCOLOGY

IMMUNOLOGY

OPHTHALMOLOGY

Biosimilars play an important role in our commitment by offering additional therapeutic options to more expensive biologics.

It is expected that biosimilars will bring between 8 to 43% savings to the Canadian biologics market place.

  • A GROWING PORTFOLIO

    We have one of the industry’s largest and most diverse portfolios: 16 biosimilars, including insulin analogs, are in development.

    They include many of the top biologics globally and are focused in the areas of oncology, immunology, endocrinology and ophthalmology.

     

  • INDUSTRY-WIDE SAVINGS


    Organizations project that the United States would save $250 billion over ten years if just the 11 likeliest biosimilars would enter the market.

    It is expected that biosimilars will bring between 8 to 43% savings to the Canadian biologics market place.

Biosimilars Value
Biosimilars Value
Hand Biologic
Hand Biologic
Hand Biologic

MANUFACTURING EXPERTISE

experience that counts

Both reference products and biosimilar medicines are made under carefully controlled conditions, known as Good Manufacturing Practices (GMP), to ensure that they are consistently produced to the required quality.

Mylan has made medicines for nearly 60 years and has a long history of manufacturing complex products.

Of our nearly 50 manufacturing sites around the world, 10 focus on product technology development, including biosimilars and respiratory products. One of our state-of-the-art complex analytical laboratories is located in Morgantown, West Virginia and is helping us lead the way in biosimilar development.

Hand Biologic
Hand Biologic
Hand Biologic
  • CENTERS OF EXCELLENCE

CONTACT US

we’re easy to access

Canada Office 
85 Advance Rd.
Etobicoke, ON 
M8Z 2S6


Contact Mylan

© 2019 Mylan Pharmaceuticals ULC. All rights reserved.
MUL-2018-0184E – JL2019


References:
1. Patented Medicine Prices Review Board. 2018. Potential Savings from Biosimilars in Canada. Available at: http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1304. [Retrieved 09 October 2018].
2. Mylan. Data on file
3. Biosimilars Canada: Canadian Biologic Drug Market 12 months ending September 2018